Alexion cutting 600 jobs and moving headquarters in major shakeup

Alexion Pharmaceuticals, until recently seen as one of biotech’s biggest success stories, is eliminating roughly 600 jobs and moving its headquarters to Boston amid federal investigations and pressure to cut costs. The company made its name on Soliris, a treatment for rare diseases that – at a cost of about $700,000 a year – is also…